Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
A6NNM8

UPID:
TTL13_HUMAN

ALTERNATIVE NAMES:
Tubulin tyrosine ligase like 13; Tubulin tyrosine ligase-like family member 13 pseudogene; Tubulin--tyrosine ligase-like protein 13

ALTERNATIVE UPACC:
A6NNM8

BACKGROUND:
The enzyme Tubulin polyglutamylase TTLL13, alternatively named Tubulin tyrosine ligase-like family member 13 pseudogene, is pivotal in the post-translational modification of tubulin. It catalyzes the elongation of polyglutamate side chains, a process essential for the proper functioning of tubulin, with a preference for alpha-tubulin over beta-tubulin.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Tubulin polyglutamylase TTLL13 holds promise for unveiling novel therapeutic avenues. Its specific enzymatic action on tubulin, a key component of the cellular cytoskeleton, underscores its potential significance in disease modulation and treatment.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.